Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Higher dose of new antimalarial drug reduces disease recurrence by 85%

A new antimalarial drug is being introduced at a dose that is too low to be effective for all patients who need it, according to a report published today in eLife.

6 Dec 2022

The critical role of flow cytometry in CAR+ T-Cell trials

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

From Cerba Research 6 Dec 2022

Pt(IV)-conjugated drug-delivery system shows efficacy in glioblastoma therapy

A recent study demonstrated a novel method for delivering anti-cancer drugs, conjugated to modified cell-penetrating peptides across the blood-brain barrier, in mice to treat glioblastoma.

18 Nov 2022

Exploring antiviral drug combinations for SARS-CoV-2 suppression

Researchers assessed the impact of drug combinations on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suppression.

14 Nov 2022

Mercury exposure during pregnancy could boost growth rates of fetus and infant

In a new study, researchers used a physiologically-based pharmacokinetic (PBPK) model to calculate the predicted concentration of MeHg in a given organ with time.

10 Nov 2022

Researchers use lasso-grafting for designing receptor agonists with enhanced pharmacokinetics

Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions like Alzheimer's disease is challenging as they are either cleared out of the blood very quickly or do not penetrate neural tissue effectively.

8 Nov 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Antibody-mediated protection against symptomatic COVID achieved at low serum neutralizing titers

In a recent study posted to the medRxiv* preprint server, researchers in the United States assessed the efficiency of protection mediated by antibodies against symptomatic coronavirus disease 2019 (COVID-19) at low serum-neutralizing titers.

24 Oct 2022

Study reviews hydroxychloroquine and remdesivir antiviral potency against SARS‐CoV‐2

In a new study, researchers outlined the synthesis and the possible mechanism of action (MOA) of two potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) repurposing drug candidates.

17 Oct 2022

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

Are men or women impacted more by adverse reactions to prescription drug treatments?

Recently, researchers presented an overview of sex-based differences in adverse drug reactions (ADRs) based on epidemiology, technique, and underlying mechanism data.

11 Oct 2022

Vitamin supplements can benefit cystic fibrosis patients, study suggests

Cystic fibrosis patients who supplement their diet with vitamin C can also derive greater benefit from another antioxidant, vitamin E, resulting in a reduction in damaging inflammation, a study led by Oregon State University suggests.

28 Sep 2022

Investigating a potential new treatment for glioblastomas

A research question posed in Pankaj Desai's lab has led to a decade of research, a clinical trial and major national funding to further investigate a potential new treatment for the most deadly form of brain tumors.

23 Sep 2022

Recent developments in the use of nanoparticles to deliver drugs to the brain via intranasal administration

Scientists have recently reviewed research articles related to the application of inorganic nanoparticles in delivering drugs to the brain through the intranasal route.

7 Sep 2022

Targeting Gαq/11 may be an efficient therapeutic strategy against uveal melanoma

Announcing a new article publication from Acta Pharmaceutica Sinica B. Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies.

5 Sep 2022

Temporo-spatial pharmacometabolomics method to evaluate microregional effect of OLZ on brain tissue

Announcing a new article publication from Acta Pharmaceutica Sinica B. The brain is the most advanced organ with various complex structural and functional microregions.

5 Sep 2022

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

Antiviral activity of favipiravir against Zika and SARS-CoV-2 in cynomolgus macaques

A new study determines the antiviral efficacy of favipiravir against ZIKV and SARS-CoV-2 infections.

4 Sep 2022

The safety, tolerability, and pharmacokinetics of a muco-trapping monoclonal antibody delivered by inhalation

Researchers conducted a phase I clinical trial of IN-006, an inhaled monoclonal antibody treatment for COVID-19.

24 Aug 2022

Next-generation monoclonal antibody prevents malaria

Researchers investigate the pharmacokinetics and safety of L9LS, a monoclonal antibody to prevent malaria.

9 Aug 2022